Clinical Trials Directory

Trials / Conditions / Lymphoma, Small Lymphocytic

Lymphoma, Small Lymphocytic

19 registered clinical trials studyying Lymphoma, Small Lymphocytic — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymph
NCT07218341
Eli Lilly and CompanyPhase 4
RecruitingA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refract
NCT05947851
Merck Sharp & Dohme LLCPhase 3
CompletedIntermittent Fasting and CLL/SLL
NCT04626843
Eleah StringerPhase 1
TerminatedObservational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
NCT04342117
SecuraBio—
RecruitingLong-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619
Medical College of Wisconsin—
RecruitingStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Le
NCT03331198
Juno Therapeutics, a Subsidiary of CelgenePhase 1 / Phase 2
UnknownEfficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepa
NCT02991638
The University of Hong KongPhase 3
WithdrawnMulticenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Sm
NCT02677948
University of Michigan Rogel Cancer CenterPhase 1 / Phase 2
TerminatedDuvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NCT02292225
SecuraBioPhase 1
CompletedTandem Auto-Allo Transplant for Lymphoma
NCT01181271
Massachusetts General HospitalPhase 2
TerminatedA Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory
NCT01005979
Emory UniversityPhase 1
CompletedCombination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Ritux
NCT00783367
Abramson Cancer Center at Penn MedicinePhase 2
TerminatedEL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00636155
David RizzieriPhase 2
CompletedPh I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
NCT00546793
Gilead SciencesPhase 1 / Phase 2
TerminatedRituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
NCT00290407
University of LouisvillePhase 2
CompletedFludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00143065
Ohio State University Comprehensive Cancer CenterPhase 2
TerminatedA Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
NCT00083473
Titan PharmaceuticalsPhase 2
CompletedDose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060684
CTI BioPharmaPhase 1
CompletedA Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
NCT00081809
Agenus Inc.Phase 2